DHA Supplementation in Patients With STGD3

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Paul S. Bernstein, University of Utah
ClinicalTrials.gov Identifier:
First received: January 10, 2007
Last updated: May 8, 2016
Last verified: May 2016
We have found that biomarkers of long-term elevated dietary intake of omega-3 fatty acids such as DHA and EPA are inversely associated with severity of disease phenotype in STGD3 patients. Therefore, the purpose of this study is to follow STGD3 patients as they supplement their diets with DHA/EPA.

Condition Intervention
Dominantly Inherited Stargardt's Disease (STGD3)
Dietary Supplement: Over the counter DHA/EPA dietary supplementation

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Clinical Interventions Against Stargardt Macular Dystrophy: DHA Supplementation in Patients With STGD3

Resource links provided by NLM:

Further study details as provided by University of Utah:

Primary Outcome Measures:
  • ERG [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Visual acuity [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Enrollment: 11
Study Start Date: August 2006
Estimated Study Completion Date: March 2017
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Single Arm, Open Label
Single Arm, Open Label
Dietary Supplement: Over the counter DHA/EPA dietary supplementation
1000 mg/day DHA/EPA


Ages Eligible for Study:   18 Years to 105 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All Moran Eye Center patients with STGD3

Exclusion Criteria:

  • All others
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00420602

United States, Utah
Moran Eye Center, University of Utah
Salt Lake City, Utah, United States, 84132
Sponsors and Collaborators
University of Utah
Principal Investigator: Paul S. Bernstein, MD Ph.D. University of Utah
  More Information

Responsible Party: Paul S. Bernstein, Professor of Ophthalmology, University of Utah
ClinicalTrials.gov Identifier: NCT00420602     History of Changes
Other Study ID Numbers: DHA STGD3 
Study First Received: January 10, 2007
Last Updated: May 8, 2016
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on May 30, 2016